Business Description
AbbVie Inc
NAICS : 325412
SIC : 5122
ISIN : US00287Y1091
Share Class Description:
FRA:4AB: Ordinary SharesTotal Employee Number:
57,000Compare
Compare
Traded in other countries / regions
ABBV.USA0QCV.UKABBV.CanadaABBV34.BrazilABBV.Argentina4AB.GermanyABBV.Mexico1ABBV.ItalyABBV.AustriaABBV.SwitzerlandABBVCL.Chile4AB.Bulgaria IPO Date
2012-12-12Description
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.13 | |||||
Equity-to-Asset | -0.05 | |||||
Debt-to-Equity | -10.95 | |||||
Debt-to-EBITDA | 4.31 | |||||
Interest Coverage | 7.16 | |||||
Piotroski F-Score | 5/9 | |||||
Altman Z-Score | 2.35 | |||||
Beneish M-Score | -2.68 | |||||
WACC vs ROIC | ||||||
Growth Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 1.8 | |||||
3-Year EBITDA Growth Rate | -9.9 | |||||
3-Year EPS without NRI Growth Rate | -10.1 | |||||
3-Year FCF Growth Rate | -9.7 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 20.83 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 8.62 |
Momentum Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 82.98 | |||||
9-Day RSI | 80.91 | |||||
14-Day RSI | 77.47 | |||||
3-1 Month Momentum % | 4.07 | |||||
6-1 Month Momentum % | -2.61 | |||||
12-1 Month Momentum % | 17.01 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 0.8 | |||||
Quick Ratio | 0.68 | |||||
Cash Ratio | 0.22 | |||||
Days Inventory | 96.79 | |||||
Days Sales Outstanding | 73.15 | |||||
Days Payable | 64.77 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Dividend Yield % | 2.55 | |||||
Dividend Payout Ratio | 0.65 | |||||
3-Year Dividend Growth Rate | 5.2 | |||||
Forward Dividend Yield % | 2.66 | |||||
5-Year Yield-on-Cost % | 3.51 | |||||
Shareholder Yield % | 2.86 |
Profitability Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 70.68 | |||||
Operating Margin % | 33.18 | |||||
Net Margin % | 5.79 | |||||
EBITDA Margin % | 26.94 | |||||
FCF Margin % | 31.77 | |||||
OCF Margin % | 33.75 | |||||
ROE % | Neg. Equity | |||||
ROA % | 2.68 | |||||
ROIC % | 11.24 | |||||
3-Year ROIIC % | 355.44 | |||||
ROC (Joel Greenblatt) % | 162.62 | |||||
ROCE % | 9.32 | |||||
Years of Profitability over Past 10-Year | 10 | |||||
Moat Score | 8 | |||||
Tariff Resilience Score | 8 |
GF Value Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 128.61 | |||||
Forward PE Ratio | 18.26 | |||||
PE Ratio without NRI | 25.62 | |||||
Shiller PE Ratio | 55.61 | |||||
Price-to-Owner-Earnings | 51.78 | |||||
PS Ratio | 7.37 | |||||
Price-to-Free-Cash-Flow | 23.17 | |||||
Price-to-Operating-Cash-Flow | 21.81 | |||||
EV-to-EBIT | 59.06 | |||||
EV-to-Forward-EBIT | 20.46 | |||||
EV-to-EBITDA | 31.01 | |||||
EV-to-Forward-EBITDA | 16.12 | |||||
EV-to-Revenue | 8.35 | |||||
EV-to-Forward-Revenue | 7.8 | |||||
EV-to-FCF | 26.26 | |||||
Price-to-GF-Value | 1.23 | |||||
Price-to-Projected-FCF | 2.56 | |||||
Price-to-Median-PS-Value | 1.64 | |||||
Earnings Yield (Greenblatt) % | 1.69 | |||||
FCF Yield % | 4.33 | |||||
Forward Rate of Return (Yacktman) % | -2.16 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return %
Total Annual Return %
AbbVie Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 53,981.395 | ||
| EPS (TTM) (€) | 1.744 | ||
| Beta | 0.3927 | ||
| 3-Year Sharpe Ratio | 0.85 | ||
| 3-Year Sortino Ratio | 1.51 | ||
| Volatility % | 22.83 | ||
| 14-Day RSI | 77.47 | ||
| 14-Day ATR (€) | 4.239266 | ||
| 20-Day SMA (€) | 204.6125 | ||
| 12-1 Month Momentum % | 17.01 | ||
| 52-Week Range (€) | 157.2 - 227.4 | ||
| Shares Outstanding (Mil) | 1,766.79 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
AbbVie Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
AbbVie Inc Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-10-30 08:00 | In 116 days | ||
| Third quarter earnings results for 2026 | 2026-10-30 | In 115 days | ||
| Second quarter earnings conference call for 2026 | 2026-07-31 08:00 | In 25 days | ||
| Second quarter earnings results for 2026 | 2026-07-31 | In 24 days | ||
| USD 1.730000 Cash Dividend | 2026-07-15 | In 8 days | ||
| Goldman Sachs 47th Annual Global Healthcare Conference | 2026-06-09 09:40 | 195.55 (-0.36%) | ||
| Bank of America Securities Healthcare Conference | 2026-05-13 13:20 | 176.35 (+2.86%) | ||
| General meeting for 2026 | 2026-05-08 09:00 | 173.75 (+0.06%) | ||
| First quarter earnings conference call for 2026 | 2026-04-29 08:00 | 169.15 (-0.03%) | ||
| First quarter earnings results for 2026 | 2026-04-29 | 169.15 (-0.03%) |
Show
Entries
AbbVie Inc Frequently Asked Questions
What is AbbVie Inc(FRA:4AB)'s stock price today?
The current price of FRA:4AB is €225.70. The 52 week high of FRA:4AB is €227.40 and 52 week low is €157.20.
When is next earnings date of AbbVie Inc(FRA:4AB)?
The next earnings date of AbbVie Inc(FRA:4AB) is 2026-07-31.
Does AbbVie Inc(FRA:4AB) pay dividends? If so, how much?
The Dividend Yield % of AbbVie Inc(FRA:4AB) is 2.55% (As of Today), Highest Dividend Payout Ratio of AbbVie Inc(FRA:4AB) was 0.66. The lowest was 0.41. And the median was 0.47. The Forward Dividend Yield % of AbbVie Inc(FRA:4AB) is 2.66%. For more information regarding to dividend, please check our Dividend Page.
Press Release
Articles on AbbVie Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers